Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris healthcare limited - tolkapon - parkinsonova bolest - anti-parkinsonove bolesti lijekovima, drugim дофаминергических posrednika - tasmar je indiciran u kombinaciji s levodopom / benserazide ili levodope / carbidopa bolesnicima s levodope reagira idiopatske parkinsonove bolesti i motoričke fluktuacije, koji nisu ili se ne podnose druge catechol-o-methyltransferase (comt) inhibitori. zbog rizika od potencijalno smrtonosne, akutnog oštećenja jetre, tasmar ne treba shvatiti kao prizemlju, kuhinju, blagovaonu-linija terapije za леводопы / бенсеразида ili леводопы / карбидопы. s tasmar treba koristiti samo u kombinaciji s lijekovima леводопы / бенсеразида i леводопы / карбидопы da se informacije o učinku tih lijekova леводопы i odnosi se na njihova istodobna primjena s tasmar.

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris healthcare limited - imikimod - keratosis; keratosis, actinic - antibiotici i kemoterapeutici za dermatološku uporabu - zyclara indicirana je za topikalno liječenje klinički tipične, ne-očigledni, sobe-hipertrofična, vidljiv ili opipljiv aktinička keratoza cijelo lice ili proćelav vlasišta u odraslih imunokompetentnih osoba kada su druge mogućnosti topikalna liječenje kontraindicirana ili manje prikladno.

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris healthcare limited - imikimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiotici i kemoterapeutici za dermatološku uporabu - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresivi - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za više informacija, molimo pogledajte odjeljak 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dislipidemije - sredstva za modifikaciju lipida - cholib je indiciran kao dodatna terapija dijeti i tjelovježbi u odraslih bolesnika visokim s mješovitim dislipidemijom za smanjenje triglicerida i povećanje razine hdl c kad ldl c razinama adekvatno upravlja pomoću odgovarajuće doze monoterapije simvastatinom.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - rasagilin tartarat - parkinsonova bolest - antiparkinsonski lijekovi - rasagiline mylan je indiciran za liječenje idiopatska parkinsonova bolest (pd) kao monoterapija (bez levodope) ili kao dodatak terapija (s levodopom) u bolesnika s kraja doze fluktuacije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - memantin hidroklorid - alzheimerova bolest - other anti-dementia drugs, psychoanaleptics, - liječenje bolesnika s umjerenom ili teškom alzheimerovom bolesti.